PMV PHARMACEUTICALS, INC. Variable Lease, Cost
PMV PHARMACEUTICALS, INC. (PMVP) reported Variable Lease, Cost of $1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2026-06-30 was $1.00K, a 94.44% decline year-over-year.
- PMV PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2026-03-31 was $20.00K, a 17.65% increase year-over-year.
- PMV PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2025-12-31 was $19.00K, a 90.00% increase year-over-year.
- PMV PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2025-09-30 was $20.00K, a 86.30% decline year-over-year.
- PMV PHARMACEUTICALS, INC. variable lease, cost for fiscal 2025 was $73.00K, a 85.88% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. variable lease, cost for fiscal 2024 was $517.00K, a 43.44% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. variable lease, cost for fiscal 2023 was $914.00K, a 7.77% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. variable lease, cost for fiscal 2022 was $991.00K, a 40.77% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-14 | $21.00K 10-Q · filed 2026-08-14 | $40.00K derived: sum of 3 quarters · filed 2026-08-14 | $60.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-12 | $39.00K derived: sum of 2 quarters · filed 2026-05-12 | $59.00K derived: sum of 3 quarters · filed 2026-05-12 | $77.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $39.00K derived: sum of 2 quarters · filed 2026-03-06 | $57.00K derived: sum of 3 quarters · filed 2026-08-14 | $73.00K 10-K · filed 2026-03-06 |
| 2025-09-30 | $20.00K 10-Q · filed 2025-11-12 | $38.00K derived: sum of 2 quarters · filed 2026-08-14 | $54.00K 10-Q · filed 2025-11-12 | $65.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $18.00K 10-Q · filed 2026-08-14 | $34.00K 10-Q · filed 2026-08-14 | $45.00K derived: sum of 3 quarters · filed 2026-08-14 | $191.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $17.00K 10-Q · filed 2026-05-12 | $27.00K derived: sum of 2 quarters · filed 2026-05-12 | $173.00K derived: sum of 3 quarters · filed 2026-05-12 | $401.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $156.00K derived: sum of 2 quarters · filed 2026-03-06 | $384.00K derived: sum of 3 quarters · filed 2026-03-06 | $517.00K 10-K · filed 2026-03-06 |
| 2024-09-30 | $146.00K 10-Q · filed 2025-11-12 | $374.00K derived: sum of 2 quarters · filed 2025-11-12 | $507.00K 10-Q · filed 2025-11-12 | $629.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $228.00K 10-Q · filed 2025-08-07 | $361.00K 10-Q · filed 2025-08-07 | $483.00K derived: sum of 3 quarters · filed 2026-03-06 | $644.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $133.00K 10-Q · filed 2025-05-09 | $255.00K derived: sum of 2 quarters · filed 2026-03-06 | $416.00K derived: sum of 3 quarters · filed 2026-03-06 | $727.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $283.00K derived: sum of 2 quarters · filed 2026-03-06 | $594.00K derived: sum of 3 quarters · filed 2026-03-06 | $914.00K 10-K · filed 2026-03-06 |
| 2023-09-30 | $161.00K 10-Q · filed 2024-11-07 | $472.00K derived: sum of 2 quarters · filed 2024-11-07 | $792.00K 10-Q · filed 2024-11-07 | $1.14M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $311.00K 10-Q · filed 2024-08-08 | $630.00K 10-Q · filed 2024-08-08 | $978.00K derived: sum of 3 quarters · filed 2025-03-03 | $1.23M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $319.00K 10-Q · filed 2024-05-09 | $667.00K derived: sum of 2 quarters · filed 2025-03-03 | $914.00K derived: sum of 3 quarters · filed 2025-03-03 | $1.11M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $595.00K derived: sum of 2 quarters · filed 2025-03-03 | $793.00K derived: sum of 3 quarters · filed 2025-03-03 | $991.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $247.00K 10-Q · filed 2023-11-09 | $445.00K derived: sum of 2 quarters · filed 2023-11-09 | $643.00K 10-Q · filed 2023-11-09 | $876.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $198.00K 10-Q · filed 2023-08-09 | $395.00K 10-Q · filed 2023-08-09 | $629.00K derived: sum of 3 quarters · filed 2024-02-29 | $787.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $197.00K 10-Q · filed 2023-05-10 | $431.00K derived: sum of 2 quarters · filed 2024-02-29 | $589.00K derived: sum of 3 quarters · filed 2024-02-29 | $781.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $392.00K derived: sum of 2 quarters · filed 2024-02-29 | $584.00K derived: sum of 3 quarters · filed 2024-02-29 | $704.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $158.00K 10-Q · filed 2022-11-08 | $350.00K derived: sum of 2 quarters · filed 2022-11-08 | $470.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $192.00K 10-Q · filed 2022-08-09 | $311.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $95.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |